STOCK TITAN
  1. Home
  2. Sec-filings
  3. TMO
  4. [Form 4] THERMO FISHER SCIENTIFIC INC. Insider Trading Activity

Thermo Fisher (NYSE: TMO) CEO exercises 10,000 options, sells 15,000 shares

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Thermo Fisher Scientific Chairman & CEO Marc N. Casper exercised 10,000 stock options at $309.63 per share on August 5, 2026, acquiring an equal number of common shares, and then, together with an affiliated entity, sold 15,000 shares at weighted‑average prices between $565.86 and $577.63 under a Rule 10b5‑1 trading plan adopted April 27, 2026. The exercised option grant now shows 30,550 options remaining, expiring February 25, 2027.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider CASPER MARC N
Role Chairman & CEO
Sold 15,000 shs ($8.63M)
Approx. gross sale proceeds $8.63M
Approx. exercise cost $3.10M
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F15 10,000 $0.00 $0.00
Exercise Common Stock 10,000 $309.63 $3.10M
Sale Common Stock F1, F2 157 $566.25 $89K
Sale Common Stock F1, F3 130 $567.92 $74K
Sale Common Stock F1, F4 105 $569.24 $60K
Sale Common Stock F1 53 $569.76 $30K
Sale Common Stock F1, F5 135 $571.49 $77K
Sale Common Stock F1, F6 431 $573.08 $247K
Sale Common Stock F1, F7 1,186 $574.03 $681K
Sale Common Stock F1, F8 2,223 $574.98 $1.28M
Sale Common Stock F1, F9 2,930 $576.05 $1.69M
Sale Common Stock F1, F10 2,575 $576.82 $1.49M
Sale Common Stock F1, F11 75 $577.56 $43K
Sale Common Stock F1, F12 79 $566.26 $45K
Sale Common Stock F1, F3 66 $567.94 $37K
Sale Common Stock F1, F13 38 $569.13 $22K
Sale Common Stock F1, F14 40 $569.69 $23K
Sale Common Stock F1, F5 68 $571.50 $39K
Sale Common Stock F1, F6 216 $573.08 $124K
Sale Common Stock F1, F7 590 $574.03 $339K
Sale Common Stock F1, F8 1,113 $574.98 $640K
Sale Common Stock F1, F9 1,464 $576.05 $843K
Sale Common Stock F1, F10 1,289 $576.83 $744K
Sale Common Stock F1, F11 37 $577.56 $21K
Holdings After Transaction: Stock Option (Right to Buy) — 30,550 shares (Direct); Common Stock — 123,925.358 shares (Direct); Common Stock — 9,608 shares (Indirect, By Floral Park Associates, Inc.)
Footnotes (15)
  1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive.
  5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive.
  6. F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive.
  7. F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive.
  8. F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive.
  9. F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive.
  10. F10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive.
  11. F11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive.
  12. F12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive.
  13. F13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive.
  14. F14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive.
  15. F15. The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024.
Shares sold 15000 shares Total Thermo Fisher common shares sold in reported transactions on August 5, 2026, per transaction summary
Options exercised 10000 shares Stock options (right to buy) for 10,000 underlying common shares exercised on August 5, 2026
Option exercise price $309.63 per share Conversion or exercise price for the 10,000 stock options exercised into common stock
Remaining options 30550 options Stock Option (Right to Buy) position held directly by Marc N. Casper after the reported exercise; expires February 25, 2027
10b5-1 plan adoption date April 27, 2026 Date Marc N. Casper adopted the Rule 10b5-1 trading plan governing these transactions
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title lists Stock Option (Right to Buy) as the derivative security"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did Thermo Fisher (TMO) CEO Marc Casper report?
Marc N. Casper reported exercising 10,000 stock options at $309.63 per share into common stock and, on the same date, he and an affiliated entity sold a combined 15,000 Thermo Fisher shares in multiple open-market transactions.

How many Thermo Fisher (TMO) shares did Marc Casper sell and at what prices?
The filings show sales totaling 15,000 shares of Thermo Fisher common stock. The reported per-share prices are weighted averages, with transaction ranges disclosed in footnotes spanning from $565.86 to $577.63 across different sale tranches.

Were Marc Casper’s Thermo Fisher (TMO) trades made under a Rule 10b5-1 plan?
Yes. A footnote states all reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Marc N. Casper on April 27, 2026, and the Form 4 indicates the Rule 10b5-1 checkbox as affirmatively selected.

What stock options in Thermo Fisher (TMO) did Marc Casper exercise?
He exercised 10,000 stock options (Stock Option – Right to Buy) at an exercise price of $309.63 per share, receiving 10,000 common shares. A footnote explains this option vested in four equal installments from 2021 through 2024 and expires on February 25, 2027.

How many Thermo Fisher (TMO) options does Marc Casper still hold after these trades?
After exercising 10,000 options, the filing reports 30,550 stock options (right to buy Thermo Fisher common stock) remaining from this grant. These options are held directly and carry an expiration date of February 25, 2027.

Did any Thermo Fisher (TMO) share sales involve an affiliated entity of Marc Casper?
Yes. Several sale transactions were reported as held indirectly “By Floral Park Associates, Inc.”. This indicates a portion of the 15,000 shares sold on August 5, 2026, were executed through that affiliated entity rather than solely from direct personal holdings.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CASPER MARC N
(Last)(First)(Middle)
168 THIRD AVENUE
(Street)
WALTHAM MASSACHUSETTS 02451
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/05/2026M10,000A$309.63133,925.358D
Common Stock08/05/2026S(1)157D$566.25(2)133,768.358D
Common Stock08/05/2026S(1)130D$567.92(3)133,638.358D
Common Stock08/05/2026S(1)105D$569.24(4)133,533.358D
Common Stock08/05/2026S(1)53D$569.76133,480.358D
Common Stock08/05/2026S(1)135D$571.49(5)133,345.358D
Common Stock08/05/2026S(1)431D$573.08(6)132,914.358D
Common Stock08/05/2026S(1)1,186D$574.03(7)131,728.358D
Common Stock08/05/2026S(1)2,223D$574.98(8)129,505.358D
Common Stock08/05/2026S(1)2,930D$576.05(9)126,575.358D
Common Stock08/05/2026S(1)2,575D$576.82(10)124,000.358D
Common Stock08/05/2026S(1)75D$577.56(11)123,925.358D
Common Stock08/05/2026S(1)79D$566.26(12)14,529IBy Floral Park Associates, Inc.
Common Stock08/05/2026S(1)66D$567.94(3)14,463IBy Floral Park Associates, Inc.
Common Stock08/05/2026S(1)38D$569.13(13)14,425IBy Floral Park Associates, Inc.
Common Stock08/05/2026S(1)40D$569.69(14)14,385IBy Floral Park Associates, Inc.
Common Stock08/05/2026S(1)68D$571.5(5)14,317IBy Floral Park Associates, Inc.
Common Stock08/05/2026S(1)216D$573.08(6)14,101IBy Floral Park Associates, Inc.
Common Stock08/05/2026S(1)590D$574.03(7)13,511IBy Floral Park Associates, Inc.
Common Stock08/05/2026S(1)1,113D$574.98(8)12,398IBy Floral Park Associates, Inc.
Common Stock08/05/2026S(1)1,464D$576.05(9)10,934IBy Floral Park Associates, Inc.
Common Stock08/05/2026S(1)1,289D$576.83(10)9,645IBy Floral Park Associates, Inc.
Common Stock08/05/2026S(1)37D$577.56(11)9,608IBy Floral Park Associates, Inc.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$309.6308/05/2026M10,000 (15)02/25/2027Common Stock10,000$030,550D
Explanation of Responses:
1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive.
10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive.
11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive.
12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive.
13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive.
14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive.
15. The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024.
Remarks:
One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4.
/s/ Melodie T. Morin, Attorney-in-Fact for Marc N. Casper08/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR